64% of patients excited about AI-powered nurse assistants

As artificial intelligence (AI) becomes more advanced and commonplace in medicine, patients are excited about the possibilities the technology could bring to care, according to a report released by Syneos Health Communications.

The report, which includes survey responses from 800 European and American patients and 200 caregivers, aims to provide insight into the future of AI in healthcare.

Findings included:

  • Fears of AI: The main fears patients and providers have about AI were a lack of human oversight and medical errors caused by AI slowing workflow and increasing mismanagement of care.
  • No Substitute for Your Doctor: Less than 20 percent of patients see any benefit to receiving a diagnosis or treatment recommendations from a virtual assistant.
  • Strong Comfort in Using AI to Scale and Support Nurses: 64 percent of patients reported they would be comfortable with AI virtual nurse assistants, listing the benefits of 24/7 access to answers and support, monitoring their general health and questions regarding medications. Some 72 percent of patients also noted the virtual assistant should have a realistic voice with a professional tone is more important than a human face or name.
  • Appropriate Providers of AI: Respondents ranked doctors, pharmacists and hospitals as the most trusted providers of AI. Technology companies were ranked the least trusted.

“Syneos Health Communications believes that technology giants viewing healthcare as their next big opportunity must address patient and caregiver concerns about trust, control and oversight,” said Michelle Keefe, president of Syneos Health Commercial Solutions. “A structured and deliberate multi-channel marketing and communications approach will be essential to generate the desired efficiencies and behavioral outcomes AI can achieve.”

""
Cara Livernois, News Writer

Cara joined TriMed Media in 2016 and is currently a Senior Writer for Clinical Innovation & Technology. Originating from Detroit, Michigan, she holds a Bachelors in Health Communications from Grand Valley State University.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.